Cambinol is a small molecule inhibitor primarily targeting sirtuin 1 (SIRT1) and sirtuin 2 (SIRT2), NAD⁺-dependent deacetylases involved in regulating gene expression, aging, inflammation, cell cycle control, and metabolism. It serves as a valuable research tool in studying these pathways, particularly in cancer models where it suppresses tumor cell proliferation and promotes apoptosis.

In preclinical studies, Cambinol has demonstrated potential in inhibiting the growth of hematological malignancies and solid tumors. It also blocks the NAD⁺-associated enzyme CD38, with implications for metabolic disorders and aging research.

Its cell-permeable properties make it ideal for cellular assays probing sirtuin-dependent and acetylation-related mechanisms. Although not clinically approved, Cambinol acts as a lead compound for developing selective inhibitors of epigenetic regulators for therapeutic applications in oncology and beyond.